Scholars Central

ArticlePublished 29 Aug 2024

Long-Term Safety Profile of Biologic Therapies in Rheumatoid Arthritis

Authors: Ahmad Nabil Youssef

International Journal of Clinical Rheumatology

Volume 19 · Issue 8 · Pages 198–201

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Biologic therapies have transformed the treatment landscape for rheumatoid arthritis (RA), providing targeted interventions that significantly improve clinical outcomes. However, their long-term safety profile remains a crucial consideration for clinicians and patients alike. This article reviews the available evidence on the long-term safety of various biologic agents used in RA, focusing on the risk of infections, malignancies, cardiovascular events, and other adverse effects. While biologics are generally well-tolerated, ongoing surveillance and research are essential to address potential risks and optimize patient safety. This review emphasizes the need for personalized treatment strategies that weigh the benefits of biologics against their long-term safety concerns.

Subjects

Rheumatology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in International Journal of Clinical Rheumatology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalInternational Journal of Clinical Rheumatology
  • SubjectRheumatology
  • BylineArticles whose byline prints “Ahmad Nabil Youssef”